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Introduction
The phenomenon of mixed chimerism has been exten-
sively studied for the last few years due to its potential
effect on induction of alloantigens tolerance after trans-
plantation of vascularized organs [1]. The tolerance
towards graft can improve results of the surgery and
allow avoiding or reducing of the long-lasting immuno-
suppression, hence the mixed chimerism raises such a
great interest [1,2]. Induction of the phenomenon needs
proper host preparation and haematopoietic cell trans-
plantation. Unfortunately, conditioning of the patient
for mixed chimerism can cause serious side effects
related to destruction of haematopoietic and immuno-
logical system [2,3]. To avoid the complications of
chimerism induction, many attempts have been made to
establish the conditioning strategy which possess pos-
sibly lowest toxicity. Since, the toxicity substantially
results from total body irradiation (TBI) and immuno-
suppressive therapy, researchers usually try to lower
the dose of TBI and eliminate or decrease duration of
immunosuppression. TBI dose could be reduced to 
3 Gy by applying of specific anti-lymphocyte antibod-
ies, namely anti-CD3, anti-CD4, anti-CD8, anti-NK, 
as well as co-stimulation blockade using anti-CD40L
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Abstract: Studies on mixed chimerism are currently focused primarily on obtaining less toxic conditioning protocols. With
these issues in mind, we have undertaken the attempt to optimize the procedure of mixed chimerism induction in mice. In
order to reduce toxicity, we used decreasing doses of total body irradiation (TBI) together with combination of blocking
antibodies. We also tried to eliminate immunosuppression (cyclophosphamide – CP) treatment after bone marrow trans-
plantation. B6.SJL-PtprcaPep3b mice were injected with 20-30 × 106 bone marrow cells from Balb C mice. Mice were treat-
ed with TBI (3 – 1.5 – 0 Gy) on "-1" day of the experiment and blocking antibodies against CD40L ("0", and "4" days) and
additionally anti-CD8 ("-2" day) and/or anti-NK1.1 ("-3" day). Mice in certain groups also received CP (175 mg/kg) on 
"2" day. Presence of mixed chimerism was assessed in peripheral blood cells by flow cytometry on the 1st, 2nd, 3rd, 4th, 6th
and 8th weeks of the experiment by detecting of CD45.1 (characteristic for B6.SJL-PtprcaPep3b strain) and CD45.2 (char-
acteristic for Balb C strain) antigens expression. We also analyzed the percentage of peripheral blood CD8 T-cells
(CD3e/CD8a) and NK cells (Ly-49D/NK1.1). We found that reduction of TBI dose and elimination of CP decrease the rate
of mixed chimerism formation. The highest percentage of donor cells was obtained in the group of animals treated with 
3 Gy of TBI, CP and combination of anti-CD40L, anti-CD8, and anti-NK1.1 antibodies. The 3 Gy TBI was necessary to
induce stable mixed chimerism, but it could be obtained without the CP use. The percentage of CD3e/CD8a and Ly-
49D/NK1.1 cells was significantly lower in the groups of mice treated by corresponding antibodies. Moreover, we observed
the lowest number of peripheral blood Ly-49D/NK1.1 cells in the group of animals with highest mixed chimerism. Our
experiments in mice model can help in better understanding of mixed chimerism phenomenon and in selecting the method
of mixed chimerism induction with lowest possible toxicity. This also might improve the protocols of stable mixed
chimerism induction in humans, and in the future, the effectiveness of vascularized organ transplantation.
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antibody with or without CTLA4Ig [1-5]. Previous 
experiments in animal model have shown the attempts
of further reduction of TBI to 2 and 1 Gy [6]. Some-
times the TBI was even totally eliminated from the
induction protocol, but to overcome this, a significant-
ly higher number of transplanted haematopoietic cells
had to be used to effectively induce the chimerism [7].
Although less toxic preconditioning is better tolerated
by the treated patients, it can cause lower percentage of
mixed chimerism, which results in instability and inef-
fectiveness of alloantigen tolerance induction [2,6].
With all these issues in mind, we have undertaken
the attempt to optimize the procedure of mixed
chimerism induction in mice. Here we have analyzed
the outcome of different preconditioning methods with
application of: 1) various doses of TBI (3 – 1.5 – 0
Gy), 2) immunosuppresive drugs (CP 175 mg/kg – 0)
after hematopoietic cell transplantation, 3) combina-
tion of co-stimulation blockade (anti-CD40L antibody)
and/or antibodies against CD8a, and NK1.1 antigens
to test their effectiveness in chimerism induction. We
observed and assessed the kinetics of the mixed
chimerism development in peripheral blood of the
experimental mice for 8 week period. 
Since many reports showed a significant role of
CD8-lymphocytes and NK cells in graft rejection, we
analyzed mice peripheral blood CD3e/CD8a and Ly-
49D/NK1.1 cells to confirm the efficiency of antibod-
ies applied and to try to correlate the number of the
cells with effectiveness of mixed chimerism induction. 
Materials and methods
Mice. The experiments were performed on 12-16-week male Balb
C (H-2d, I-E+) and B6.SJL-PtprcaPep3b (H-2s, I-E-) mice [8]. Mice
were purchased from The Jackson Laboratory (Bar Harbor, ME,
USA). The chosen mice strains have different isoforms of the
CD45 antigen, CD45.1 (B6.SJL-PtprcaPep3b) and CD45.2 (Balb
C), which enables precise analysis of chimerism by flow cytome-
try [9]. Additionally, they possess different MHC class I and II
antigens. Mice were kept under specific pathogen-free conditions
in the BIO.S.A. Blower Unit Vent II (Ehret, Labor- and Pharmate-
chnik, Germany). 
Inducing chimerism. Each group of experimental mice consisted of
3 animals. First, we induced chimerism in 3 groups (G1-G3) to estab-
lish optimal configuration of antibodies used to detect its effective-
ness. Conditioning was based on total body irradiation of B6.SJL-
PtprcaPep3b mice with gamma chain (60Co) in 3 Gray (Gy) dose on
day – 1st of the experiment. Cyclophosphamide (Endoxan, Baxter
Oncology GmbH, Germany) in dose of 175 mg/kg was given
intraperitoneally (i.p.) on the day + 2nd. Additionally, animals were
injected i.p. with blocking antibodies against mouse NK1.1 (Anti-
NK1.1 mAb, clone PK136, Becton Dickinson, USA), CD8a (Anti-
CD8a mAb, clone 53-6.7, Becton Dickinson, USA) and CD40L
(Anti-CD154 mAb, clone MR1, Becton Dickinson, USA) as indicat-
ed in Table 1 for each group of animals. 30 × 106 of unseparated Balb
C bone marrow cells were given intravenously on day 0 (in 0.2 mL
PBS). The cells were obtained by flushing of femurs and tibias with
cold PBS (Phosphate-buffered saline) with 2% fetal bovine serum
(FBS), L-glutamine and antibiotics. After isolation, erythrocytes 
were depleted by 15-minute incubation with ammonium chloride 
containing lysing solution (BD Pharm Lyse, Lysing Buffer, Becton-
Dickinson, USA) and were passed through a 40 μm nylon mesh (Cell
Strainer, BD Falcon, Becton Dickinson, USA). Cell washing was per-
formed at 4°C each time. Because in the 1st group of animals (anti-
NK1.1 and anti-CD40L × 2) we could not obtain stable chimerism,
we excluded the combination of antibodies used in this group from
further studies. In the further part of the experiment, in the group G4
and G5 we applied identical combination of antibodies as in the
groups G2 (anti-CD8a and anti-CD40L x 2) and G3 (anti-CD8a, anti-
NK1.1, and anti-CD40L) but we resigned of CP. In the groups G6-G9
we decreased doses of TBI to 1.5 Gy (G6 and G7) and 0 Gy (G8 and
G9) (Table 1).
Detection of chimerism. A presence of mixed chimerism in the
peripheral blood leucocytes was measured using flow cytometry in
the 1st, 2nd, 3rd, 4th, 6th and 8th weeks after bone marrow cell infu-
sion based on analysis of CD45.1 (B6.SJL-PtprcaPep3b) and
CD45.2 (Balb C) antigens as previously described [8]. The data
were collected with FACScan (Becton-Dickinson, USA) and ana-
lyzed using the CellQuest program. Shortly, mouse peripheral
blood was collected to tubes with heparin from tail vain in the 1st,
2nd, 3rd, 4th, 6th weeks and from heart in the 8th week. Erythrocytes
were lysed with ammonium chloride solution for 15 min. Remain-
ing leucocytes were washed in PBS with 2% FBS by centrifugation
(1200 rpm, 4°C, 5 min) and then stained with fluorescein isothio-
cyanate (FITC)-conjugated anti-CD45.2 antibody (clone 104) and
phycoerythrin (PE)-conjugated anti-CD45.1 antibody (clone A20).
The cells were incubated with the antibodies for 30 min at 4°C,
washed and fixed with 1% formalin [9,10]. Appropriate isotype
antibodies were used as negative controls. Chimerism was ana-
lyzed in 2 × 104 cells by flow cytometry within total leucocytes
gated based on FSC/SCC diagram (FACScan, BD, USA).
Analysis of CD3e/CD8a and Ly-49D/NK1.1 cells. In the 8th week
of the experiment peripheral blood cells were stained with fluorescein
isothiocyanate (FITC)-conjugated anti-CD3e antibody (clone 145-
2C11) and phycoerythrin (PE)-conjugated anti-CD8a antibody (clone
53-6.7) to assess CD3e/CD8a cells, and FITC-conjugated anti-Ly-
49D (clone 4E5) and PE-conjugated anti-NK1.1 (clone PK136) to
analyze Ly-49D/NK1.1 cells (BD Pharmingen, Becton Dickinson,
USA) as described above. Routinely, the 2 × 104 cells were analyzed
by flow cytometry in lymphocyte gate (FACScan, BD, USA).
Ethical issues. All experiments were approved by the Local Ethi-
cal Committee and were performed in accordance with guidelines
of laboratory animal care.
Statistical analysis. The arithmetical means and standard devia-
tions were calculated using MS Excel v. 97. Next, non-parametric
tests were used because of abnormal distributions of analyzed data
(the Shapiro-Wilk test). Significances of changes in the chimerism
kinetics were evaluated with the Friedman ANOVA and the Wil-
coxon signed-rank tests. The Kruskal-Wallis ANOVA and the
Mann-Whitney tests were used to compare the percentage of
CD3e/CD8a and Ly-49D/NK1.1 cells between different groups of
animals. Statistical significance was defined as p<0.05.
Results 
Kinetics of chimerism in mice peripheral blood
in effect of various conditioning protocols use
We analyzed the percentage of mixed chimerism in the
peripheral blood leucocytes in the 1st, 2nd, 3rd, 4th, 6th
and 8th weeks of the experiment based on expression of
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two isoforms of the CD45 antigen characteristic for
each of the used mice strains (Fig. 1A). We obtained
mixed chimerism in each mice of groups G1-G7, but in
the last two groups of mice (G8-G9) we were able to
induce only microchimerism (percentage of donor cells
<1%) (Fig. 2). Among first three groups we observed
the lowest percentage of donor cells in group G1 seen
only in the 1st week of the experiment, therefore we
resigned of using combination of just anti-NK1.1 and
anti-CD40L in further experiment. Comparing G2 and
G3 groups we found the significantly higher chimerism
in the group G3 of animals (3 Gy, CP, anti-NK1.1, anti-
CD8, anti-CD40L). The percentage of mixed
chimerism was stable in the G2 and G3 groups during
the entire time of experiment.
In next steps we resigned of CP and reduced TBI
dose. As we expected, the degree of mixed chimerism
correlated with applied immunosuppression and the
dose of TBI. Elimination of CP lowered percentage of
donor cells when comparing groups G3 and G5, but
the differences were not statistically significant
between groups G2 and G4. The great impact on
chimerism induction and maintaining had the TBI
dose. Decreasing it to 1.5 Gy lowered significantly
percentage of chimerism as measured in each sched-
uled time interval. Resignation of TBI failed to induce
mixed chimerism in the G8 and G9 mice. 
Analysis of mice peripheral blood CD8 T-cells
(CD3e/CD8a) and NK cells (Ly-49D/NK1.1)
We also investigated the percentage of CD3e/CD8a
and Ly-49D/NK1.1 cells in mice peripheral blood in
the 8th week of the experiment (Fig. 1B, 1C). We
observed that each group of mice that received anti-
CD8a or anti-NK1.1 antibodies showed lower number
of CD3e/CD8a (p<0.05) (Fig. 3) and Ly-49D/NK1.1
(p<0.05) (Fig. 4) cells. Analysis of CD3e/CD8a cells
demonstrated the lowest number of the cells in the G4
mice (3 Gy, anti-CD8, anti-CD40Lx2), however the
difference was not statistically significant. The per-
centage of CD3e/CD8a cells did not correlate with the
level and stability of mixed chimerism. However, we
observed that the number of Ly-49D/NK1.1 cells was
reduced in the G3 group where percentage of mixed
chimerism was the highest.
Discussion
The main problem with obtaining mixed chimerism is
toxicity of the pretreatment strategy. Pretreatment of
host can cause many side effects like infection, risk
of bone marrow relapse or graft versus host disease
(GvHD). Until the problem is resolved, application of
this method in tolerance induction will remain limit-
ed [2,11].
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Table. 1. The conditioning strategies.
First studies on mixed chimerism used myeloabla-
tive doses of TBI combined with immunosuppressive
drugs [2,12]. Since that conditioning was toxic to the
recipient, many affords have been made to lower the
dose of TBI to 3 Gy. But decreasing the TBI dose
needs, besides the use of immunosuppressive drugs,
also the anti-lymphocyte antibodies treatment. Cur-
rently, large diversity of antibodies are applied in pro-
tocols of mixed chimerism induction, starting from
anti-CD3, anti-CD4, anti-CD8 antibodies to common-
ly used costimulation blockade (anti-CD40L with/with-
out CTLA4Ig) and previously reported anti-NK1.1
antibodies [1-4,7,13]. Besides the possibility of lower-
ing the dose of TBI, antibodies can shorten the time of
immunosuppression after transplantation. There are
many of conditioning strategies that use 3 Gy of TBI,
anti-lymphocyte antibodies and short-time immuno-
suppression. Recent reports suggest that TBI dose can
be reduced to 2 or 1 Gy when combined with immuno-
suppressive drugs [6]. Also, the elimination of TBI was
reported in the protocol which included only the cos-
timulation blockade with antibodies, but that required
injection of larger amount of haematopoietic cells [2,7].
We started our experiment with the protocol based
on 3 Gy of TBI and single injection of 175 mg/kg m.c.
CP. We were applying standard doses of bone marrow
cells, since higher doses are clinically unobtainable.
We used anti-CD40L antibody, because many reports
showed that this antibody inhibited effectively CD4
cells and helped inducing tolerance [4,5,14]. This anti-
body blocks second signal that is essential for full 
T-cell activation and differentiation of naive T cells
into effector T cells [1,2,5].   
Besides CD4-lymphocytes, which play central role
in alloresponse, the cytotoxic CD8-lymphocytes acti-
vated by CD4 cells also take part in graft rejection
[3,4,6]. Since costimulation blockade did not prevent
all of the CD8 cell-mediated allografts rejections, we
used anti-CD8a antibody to block the CD8 cells
[5,13,15]. Many researchers effectively applied this
antibody in their induction protocols [14,16]. Anti-CD8
antibody with 3 Gy TBI and hematopoietic cell trans-
plantation developed chimerism in CD40L-/- mice [5].
On the other hand, elimination of the CD8 cells with
anti-CD8 antibody did not improve hematopoietic cell
engraftment in Westerhuis study [7]. The work of
Takeuchi showed that moving the timing of 3 Gy TBI to
day "-1" instead of day "0" of experiment allows for res-
ignation of anti-CD8 antibody [15]. Our previous exper-
iment suggested that in mice strains we used, which nor-
mally have high percentage of peripheral blood CD8
cells, the anti-CD8 antibody should be applied to obtain
mixed chimerism [8]. The results obtained in the G1
group of animals, where combination of antibodies
without anti-CD8 was not effective to induce stable
chimerism, confirmed that the above suggestion is right. 
Besides the T cells response to allograft, NK cells
have been proven to participate in the rejection, espe-
cially of xenogeneic graft [7,13]. They are important in
acute rejection, prior to T-cell reaction against 
the hematopoietic stem cells [7]. The chimerism was
also better induced after elimination of the NK cells
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Fig. 1. Examples of flow cytometry analyses: A – chimerism (FL1 –
CD45.2-FITC – donor cells; FL2 – CD45.1-PE – recipient cells); B
– the CD3e/CD8a cells (FL1 – CD3e-FITC; FL2 – CD8a-PE); C –
the NK1.1/Ly-49D cells (FL1 – Ly-49D-FITC; FL2 – NK1.1-PE) Fig. 2. Kinetics of chimerism in the peripheral blood leukocytes
after various conditioning strategies applying.
Fig. 3. The percentage of peripheral blood CD3e/CD8a cells in the
8th week of the experiment.
Fig. 4. The percentage of peripheral blood NK1.1/Ly-49D cells in
the 8th week of the experiment.
[17-19]. Since, the anti-NK1.1 antibody was suggested
to induce mixed chimerism without TBI [7], we also
added anti-NK1.1 to our protocols to block the NK
cells. In current experiment, highest percentage of
donor cells was observed in mice that received combi-
nation of three antibodies in comparison to mice that
were given anti-CD8a and two doses of CD40L (G3
vs. G2), which further suggests the influence of NK
cells elimination on chimerism induction. 
Another part of our experiment was the attempt to
eliminate of immunosuppression treatment in condi-
tioning protocols. Cyclophosphamid, applied in G1-
G3, induces immunoablation that helps to avoid graft
relapse, but causes side effects, such like infection,
mostly due to lymphopenia and lymphocyte suppres-
sion, but also neutropenia, cystitis, interstitial pneumo-
nia, gonad and heart injury [20]. As we supposed,
avoidance of immunosuppression decreased percent-
age of donor cells in chimeric mice. It was clearly
observed in the G5 mice, where chimerism was signif-
icantly lower in comparison to G3, and decreased even
more in the 8th week of the experiment. In this group
of animals anti-NK1.1 antibody was used instead of
one dose of anti-CD40L. These results suggest that
single dose of the CD40L antibody (0.5 mg) without
CP is not sufficient to block T-cell response. Conse-
quently, this procedure is not as effective as in the G4
mice, where two doses of CD40L and anti-CD8 anti-
bodies were applied. We state that induction of mixed
chimerism is possible without immunosuppression but
needs instead the set of precisely selected antibodies. 
As a next step of the experiment we reduced the TBI
dose to 1.5 Gy using previously established protocols
with antibodies and without CP. Mixed chimerism was
significantly lower in the G6 group (max. 5.05%) as
well as in the G7 mice (max. 8.76%), and it diminished
with the time of experiment. Moreover, elimination of
TBI induced only the microchimerism in treated mice.
We proved in present experiment, that reduction of the
TBI dose did not give stable chimerism when immuno-
suppression was not used. Other authors' observations
that showed possibility of TBI elimination may be
explained by different mice strains combinations, since
protocols using MHC-mismatched mice with the same
genetic background provide higher potential of creating
mixed chimerism. Another explanation may be larger
amount of transplanted cells, even 10-fold of our dose,
which for practical reasons was not possible to obtain
[2]. To date, with some exceptions, TBI is essential in
most of conditioning procedures. Although TBI is toxic
to the patients, Sogawa et al. replaced it by short-term
immunosuppression, and the 3 Gy TBI turned out to be
more effective and less toxic than CP in 200 mg/kg m.c.
dose [20]. 
In the 8th week of our study we analyzed the
CD3e/CD8a and the Ly-49D/NK1.1 cells levels in
tested animals. We wanted to prove that antibodies
we used in the experiment were effective in depleting
of the CD8 T-lymphocytes and NK cells. We also
wanted to test whether such elimination of the cells
responsible for graft rejection plays any important
role in mixed chimerism induction or maintenance.
We expected that removing of CD8-lymphocytes was
necessary to create mixed chimerism in our mice
strain. However, we did not observe a correlation
between number of the CD3e/CD8a cells and per-
centage of chimerism. Next, we analyzed the NK
cells. Their elimination with the NK1.1 antibody
improved chimerism induction in mice in which the
CP treatment was used. On the other hand, in groups
without CP use, this antibody probably did not effec-
tively substitute the second dose of anti-CD40L,
which effected in percentage of chimerism decrease
in 8th week of experiment. We applied the NK1.1
antibody, because Westerhuis showed that it could
induce chimerism without TBI [7]. Unfortunately,
this antibody blocks also the NK T cells, a subpopu-
lation of T-lymphocytes that are thought to induce
and maintain graft tolerance by their regulatory
action, so the antibody can exert both of these some-
what contradictive effects [17,21]. The duality of the
antibody influence in blocking the NK cells as well
as the NK T cells could also explain our decreased
chimerism in the 8th week of experiment. Moreover,
Shimizu et al. showed that use of the NK1.1 antibody
induced higher level of chimerism but did not cause
transplantation tolerance, which could also confirm
our explanation [17]. 
Natural killer cells express activation receptor Ly-
49D, that mediates activation of NK-cell cytolysis.
This receptor is not detected on NK1.1 T cells [17].
Previous study showed that NK cells expressed less
Ly-49D antigen in tolerant mixed chimerism mice
[19]. In our experiment, we observed that among ani-
mals that received the anti-NK1.1 antibody the lowest
amount of the Ly-49D/NK1.1 cells was seen in the
group with highest percentage of chimerism, so the
Ly-49D/NK1.1 cells may become a good indicator of
tolerance induced in chimeric mice.
To summarize, from among our different methods
of chimerism induction, the most effective was one
with 3 Gy TBI, CP and antibodies against CD40L,
CD8a and NK1.1. The 3 Gy of TBI was necessary to
obtain stable mixed chimerism, but it can be induced
without immunosuppression (3 Gy TBI, 2x anti-
CD40L, antiCD8a). We proved the role of CD8 and
NK cell elimination in mixed chimerism induction.
Moreover, we suggest the decreasing of Ly-
49D/NK1.1 cells as the indicator of generated immune
tolerance. 
The experiments on mixed chimerism in mice
model can help in better understanding of this phe-
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nomenon and in selection of best protocol for human
purposes. The protocol can improve immune tolerance
induction and therefore the effectiveness of vascular-
ized organ transplantation. Moreover, it may help in
avoiding of long-lasting immunosuppressive therapy.
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